Mineralys CEO John Congleton describes the rational of targeting aldosterone for hypertension and discusses his company's pivotal data
- blonca9
- Sep 8, 2025
- 1 min read
He describes the science behind aldosterone and Mineralys' program lorundrostat. The company had pivotal data earlier this year and plans to have a pre-NDA meeting with FDA in the fourth quarter.
Coverage brought to you by:















.png)

